Close Menu
FintechFetch
    FintechFetch
    • Home
    • Fintech
    • Financial Technology
    • Credit Cards
    • Finance
    • Stock Market
    • More
      • Business Startups
      • Blockchain
      • Bitcoin News
      • Cryptocurrency
    FintechFetch
    Home»Stock Market»Down 13% from its year high at £116.50 now, AstraZeneca’s share price looks cheap to me anywhere under £219.81
    Stock Market

    Down 13% from its year high at £116.50 now, AstraZeneca’s share price looks cheap to me anywhere under £219.81

    FintechFetchBy FintechFetchFebruary 12, 2025No Comments3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Image source: Getty Images

    AstraZeneca’s (LSE: AZN) share price remains significantly down from its 3 September 12-month traded high of £133.38.

    Such a drop could signal that the pharmaceuticals giant is fundamentally worth less than it was before.

    Or it could flag a major bargain to be had.

    To find out which it is, I took a close look at the core business and its key valuations.

    How does the business look?

    Weighing on the share price recently has been the ongoing investigation into the firm’s Chinese operation. These include allegations of medical insurance fraud, illegal drug imports and personal information breaches. This remains a principal risk for the company, in my view.

    However, its full-year 2024 results released on 6 February showed total revenue up 21% year on year to $54.073bn (£43.59bn). Its core earnings per share (EPS) were up 19% to $8.21.

    The firm also delivered nine positive high-value Phase III studies in the year. This is the final stage before a treatment can gain regulatory approval to go to market. 

    AstraZeneca now forecasts total revenue to increase by a high single-digit percentage in 2025. It further projects that core EPS will rise by a low-double-digit percentage during that time.

    Overall, it said that 2024 “marks the beginning of an unprecedented, catalyst-rich period for our company”. It added that it is “an important step on our Ambition 2030 journey to deliver $80bn total revenue by the end of the decade”.

    Following these numbers, analysts forecast that its earnings will increase 16.97% a year to the end of 2027.

    And it is earnings growth that ultimately powers a firm’s share price (and dividend) higher.

    So, are the shares undervalued now?

    I compare a stock’s key valuations with its peers as the first part of assessing the fairness of its current share price.

    On the price-to-earnings ratio (P/E), AstraZeneca is second lowest at 31.7, above Novo Nordisk at 27.6. The remainder of the peer group comprises Pfizer at 32.4, Eli Lilly at 74.7, and AbbVie at 78.7.

    So, AstraZeneca looks very cheap on this measure.

    The same is true of its price-to-book ratio of 5.5 against a competitor average of 34. And it is also the case for its 4.1 price-to-sales ratio compared to a 10.5 peer average.

    The second part of my share price assessment looks at where a stock should be, based on future cash flow forecasts for a firm.

    The resultant discounted cash flow analysis using other analysts’ figures and my own shows AstraZeneca shares are 47% undervalued.   

    Therefore, the fair value of the stock is technically £219.81.

    It may move lower or higher than this due to the vagaries of the market, of course. But the three key ratio undervaluations and the huge discount to the DCF-derived fair value confirm to me how cheap the stock looks now.

    Will I buy more of the shares?

    Any significant dip in AstraZeneca’s share price is too tempting for me to miss.

    The company has ambitious growth targets, which I think it will hit. As a result, its earnings are likely to grow at least in line with analysts’ forecasts, in my view.

    This in turn should drive its share price (and dividend) higher over time.

    Consequently, I will be buying more of the stock very soon.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleDogecoin Ready For A $2.43 Rally? Elliott Wave Says Yes
    Next Article Ethereum’s ‘Ultra Sound Money’ Narrative Fades, But Key Metrics Signal Growth Potential
    FintechFetch
    • Website

    Related Posts

    Stock Market

    How much do you need in a SIPP to target a £1,250 monthly second income?

    August 7, 2025
    Stock Market

    Why this FTSE 100 stock is 1 for value investors to consider in 2025

    August 7, 2025
    Stock Market

    Here’s what £1k invested in Greggs shares a month ago is worth now

    August 7, 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    YouTrip Enables International Transfers to Over 40 Countries

    March 3, 2025

    FINTECH.TV: Project Nemo’s Impact on Adults with Learning Disabilities

    June 21, 2025

    Stripe: Redefining Online Payments – Fintech Review

    April 10, 2025

    3 techniques to turbocharge your SIPP for a richer retirement!

    June 15, 2025

    Africa Crypto Week in Review:  Onafriq Taps USDC, Nigeria After 8 Suspects Following CBEX Collapse, Phoenix Group Expands Bitcoin Mining Operations In Ethiopia

    May 3, 2025
    Categories
    • Bitcoin News
    • Blockchain
    • Business Startups
    • Credit Cards
    • Cryptocurrency
    • Finance
    • Financial Technology
    • Fintech
    • Stock Market
    Most Popular

    Financial Inclusion in 2025: Will Fintech Finally Close the Gaps?: By Katherine Chan

    February 24, 2025

    Burnout Costs Employers Up to $5 Million Per Year: Study

    March 11, 2025

    CapBay Thailand and OSMEP to Boost Alternative Financing for SMEs

    March 4, 2025
    Our Picks

    Stablecoin regulation is here – but what comes next for banks?: By Carlos Kazuo Missao

    August 8, 2025

    Skyee Obtains Major Payment Institution (MPI) License from the Monetary Authority of Singapore (MAS)

    August 7, 2025

    OpenAI, ChatGPT Releases ‘Smarter’ New Model: GPT-5

    August 7, 2025
    Categories
    • Bitcoin News
    • Blockchain
    • Business Startups
    • Credit Cards
    • Cryptocurrency
    • Finance
    • Financial Technology
    • Fintech
    • Stock Market
    • Privacy Policy
    • Disclaimer
    • Terms and Conditions
    • About us
    • Contact us
    Copyright © 2024 Fintechfetch.comAll Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.